Optimer^® binders are next-generation aptamer molecules derived from nucleic acids that function as an antibody alternative. Despite many well-recognised challenges with antibodies, the global antibody market is currently worth over $145 bn. Optimer^® binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.

Our vision is science unlimited. We aim to remove the scientific limits of targets, speed, stability, selectivity and specificity and more for our partners to develop better and faster life science solutions. We do this by powering scientific innovation for our partners with novel Optimer^®-based technological solutions.

Aptamer Group has developed a proprietary platform technology that drives three distinct businesses: Aptamer Solutions for custom Optimer^® development, Aptamer Diagnostics for in-house and collaborative Optimer^®-based diagnostic development and Aptamer Therapeutics for the development of Optimer^®-based therapeutics. This will generate revenue for sustained profitability in the near-term from custom projects, with long-term value creation through diagnostic and therapeutics as the Company reaches maturity.

At Aptamer Group, we have successfully delivered projects for global pharma companies, diagnostic development companies, and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through our unique technology and processes, we enable scientists and collaborators to make faster, more informed decisions that support discovery and development across the Life Sciences.